---
title: "InnoCare Announces the Acceptance of New Drug Application for Orelabrutinib in Primary Immune Thrombocytopenia in China"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287892856.md"
description: "Orelabrutinib, a BTK inhibitor, has received its initial NDA approval for treating autoimmune conditions in China. This marks the first acceptance for such use. Notably, no BTK inhibitors have been given the green light in China specifically for treating ITP, highlighting the significance of this milestone in healthcare advancements for the region."
datetime: "2026-05-28T09:24:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287892856.md)
  - [en](https://longbridge.com/en/news/287892856.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287892856.md)
generator: "portal-rs"
---

# InnoCare Announces the Acceptance of New Drug Application for Orelabrutinib in Primary Immune Thrombocytopenia in China

Orelabrutinib, a BTK inhibitor, has received its initial NDA approval for treating autoimmune conditions in China. This marks the first acceptance for such use. Notably, no BTK inhibitors have been given the green light in China specifically for treating ITP, highlighting the significance of this milestone in healthcare advancements for the region.

### Related Stocks

- [09969.HK](https://longbridge.com/en/quote/09969.HK.md)
- [688428.CN](https://longbridge.com/en/quote/688428.CN.md)
- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)
- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)
- [513120.CN](https://longbridge.com/en/quote/513120.CN.md)
- [159102.CN](https://longbridge.com/en/quote/159102.CN.md)
- [513700.CN](https://longbridge.com/en/quote/513700.CN.md)
- [159506.CN](https://longbridge.com/en/quote/159506.CN.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [159992.CN](https://longbridge.com/en/quote/159992.CN.md)
- [520690.CN](https://longbridge.com/en/quote/520690.CN.md)
- [516500.CN](https://longbridge.com/en/quote/516500.CN.md)
- [159892.CN](https://longbridge.com/en/quote/159892.CN.md)
- [520880.CN](https://longbridge.com/en/quote/520880.CN.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [159615.CN](https://longbridge.com/en/quote/159615.CN.md)
- [159837.CN](https://longbridge.com/en/quote/159837.CN.md)
- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [588130.CN](https://longbridge.com/en/quote/588130.CN.md)
- [588250.CN](https://longbridge.com/en/quote/588250.CN.md)
- [159316.CN](https://longbridge.com/en/quote/159316.CN.md)
- [159859.CN](https://longbridge.com/en/quote/159859.CN.md)

## Related News & Research

- [China NMPA clears InnoCare Phase III trial of mesutoclax-azacitidine in treatment-naive AML](https://longbridge.com/en/news/296164458.md)
- [SDIC Securities Remains a Buy on InnoCare Pharma Ltd. (9969)](https://longbridge.com/en/news/297030913.md)
- [G Sachs Raises INNOCARE  TP to HKD22.71 on Strong 2Q Sales of Orelabrutinib](https://longbridge.com/en/news/297289543.md)
- [INNOCARE Swings to Interim Profit of RMB246M](https://longbridge.com/en/news/296767336.md)
- [InnoCare swings to profit of RMB 239.7 million in H1 FY26; revenue climbs 55.5% to RMB 1.1 billion](https://longbridge.com/en/news/296802932.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**